Nonalcoholic Steatohepatitis (NASH) Clinical Trials
2 recruiting trials for Nonalcoholic Steatohepatitis (NASH). Eligibility criteria explained in plain English.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
Evaluate efficacy and safety of ADI-PEG 20 in patients with NASH
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Nonalcoholic Steatohepatitis (NASH), with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Nonalcoholic Steatohepatitis (NASH), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Nonalcoholic Steatohepatitis (NASH), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.